Generate Biomedicines, Inc · Q2 2026 earnings

Briefing

Generate Biomedicines reported Q2 2026 collaboration revenue of $6.3 million and a net loss of $67.3 million.

Generate Biomedicines Inc. reported financial results for the second quarter ended June 30, 2026, with collaboration revenue of $6.3 million, down from $10.1 million in the prior year. The company posted a net loss of $67.3 million, compared to $56.7 million a year earlier, driven by higher R&D and G&A expenses. Cash, cash equivalents, and marketable securities stood at $457.4 million, expected to fund operations into the first half of 2028.

• Q2 2026 collaboration revenue totaled $6.3 million, reflecting contributions from Amgen and Novartis programs.
• Net loss widened to $67.3 million from $56.7 million in Q2 2025 due to increased operating expenses.
• Cash position of $457.4 million provides runway into the first half of 2028.
• Clinical progress continued with Phase 3 asthma trials advancing and new Phase 1 studies underway.

Headline financials

Revenue & EPS history

Existing cash expected to fund current operating plan into first half of 2028; additional capital required for long-term operations.